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Monogenic autoinflammatory diseases are rare conditions caused by genetic
abnormalities affecting the innate immunity. Previous therapeutic strategies had been
mainly based on results from retrospective studies and physicians’ experience. However,
during the last years, the significant improvement in their genetic and pathogenic
knowledge has been accompanied by a remarkable progress in their management. The
relatively recent identification of the inflammasome as the crucial pathogenic mechanism
causing an aberrant production of interleukin 1β (IL-1β) in the most frequent monogenic
autoinflammatory diseases led to the introduction of anti–IL-1 agents and other biologic
drugs as part of the previously limited therapeutic armamentarium available. Advances in
the treatment of autoinflammatory diseases have been favored by the use of new biologic
agents and the performance of a notable number of randomized clinical trials exploring
the efficacy and safety of these agents. Clinical trials have contributed to increase the
level of evidence and provided more robust therapeutic recommendations. This review
analyzes the treatment of the most frequent monogenic autoinflammatory diseases,
namely, familial Mediterranean fever, tumor necrosis factor receptor–associated periodic
fever syndrome, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, and
cryopyrin-associated periodic syndromes, together with periodic fever with aphthous
stomatitis, pharyngitis, and cervical adenitis syndrome, which is the most common
polygenic autoinflammatory disease in children, also occurring in adult patients. Finally,
based on the available expert consensus recommendations and the highest level of
evidence of the published studies, a practical evidence-based guideline for the treatment
of these autoinflammatory diseases is proposed.
Keywords: monogenic autoinflammatory diseases, PFAPA syndrome, colchicine, anakinra, canakinumab, anti-
TNF agents, tocilizumab, Janus kinase (JAK) inhibitors
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INTRODUCTION
Over the past 20 years, pathogenic insights into the mechanisms
of autoinflammation completely changed treatment and
prognosis of many inherited autoinflammatory diseases, also
known as “hereditary periodic fever syndromes,” a group
of rare diseases characterized by difficult diagnostic and
therapeutic approaches. The most extensively studied and
better pathogenically defined monogenic autoinflammatory
conditions have been familial Mediterranean fever (FMF),
tumor necrosis factor (TNF) receptor–associated periodic
fever syndrome (TRAPS), hyperimmunoglobulin D
syndrome/mevalonate kinase deficiency (HIDS/MKD), and
cryopyrin-associated periodic syndromes (CAPS), which
comprise three disorders with the same genetic background,
and different phenotypes and outcomes. The CAPS spectrum
includes familial cold autoinflammatory syndrome (FCAS),
the mildest form; Muckle-Wells syndrome (MWS), the
intermediate presentation; and chronic infantile neurological,
cutaneous, and articular syndrome (CINCA) or neonatal-onset
multisystem inflammatory disorder (NOMID), the most severe
disease (1).
Until the late 1990s, traditional drugs, such as colchicine and
glucocorticoids, had been used to treat autoinflammatory
diseases. The pathogenic and therapeutic revolution
started when NLRP3, one of the NOD-like receptors
(NLRs) and part of the NLRP3 inflammasome, was
discovered as the main actor in the activation of caspase
1 and the subsequent production of active interleukin
1β (IL-1β) (2). Mutations of genes involved in the
inflammasome function or its related pathways were
then identified as responsible for most of the monogenic
autoinflammatory disorders recognized so far, also known as
inflammasomopathies (3).
The discovery of the aberrant production of IL-1β as the
final cause of all inflammasomopathies led to the introduction
of anti–IL-1 agents and other biologic drugs to the very limited
therapeutic armamentarium available for such diseases until
then (4). In addition, the more recent knowledge of other
autoinflammatory mechanisms, such as the activation of nuclear
factor κB (NF-κB) and type I interferon (IFN) pathways, also
provided new therapeutic options, such as anti-TNF and Janus
kinase (JAK) inhibitors agents, directed to the specific blockade
of cytokines and molecules involved in these novel inflammatory
mechanisms (5–9).
Because monogenic autoinflammatory diseases are rare
conditions, therapeutic strategies had been mainly based
on results from retrospective studies and expert physicians’
experience. Nevertheless, during the last years, the vast
improvement in their genetic and pathogenic knowledge
has been accompanied by a great effort in improving their
management. In this sense, a remarkable number of randomized
clinical trials exploring the efficacy and safety of new biologic
agents in autoinflammatory diseases have been conducted, and
therefore, therapeutic recommendations can be based now on
higher evidence levels.
OBJECTIVES AND METHODOLOGY OF
THE REVIEW
This review intends to analyze the use of conventional
and biologic agents in the most prevalent monogenic
autoinflammatory diseases (FMF, TRAPS, HIDS/MKD, and
CAPS) and periodic fever syndrome, aphthous stomatitis,
pharyngitis, and cervical adenitis (PFAPA) syndrome. Although
PFAPA syndrome is a polygenic or multifactorial disease with
an unidentified genetic background, its treatment is reviewed
because PFAPA syndrome is themost frequent autoinflammatory
condition in childhood and has to be frequently considered part
of the differential diagnosis of some monogenic disorders in
children and adults (10).
Evidence-based recommendations for the management of
FMF, TRAPS, HIDS/MKD, and CAPS have been provided
from previous consensus studies using the European League
Against Rheumatism (EULAR) standard operating procedures
for developing best practice (Table 1) (11, 12), such as the
EULAR recommendations for the management of FMF (13),
and the European SHARE (Single Hub and Access point
for pediatric Rheumatology in Europe) recommendations for
the management of CAPS, TRAPS, and MKD (14). For all
the autoinflammatory diseases, results of new clinical trials,
international multicenter collaborative studies and registries, and
retrospective data preferably from referral centers, have also
been used to generate levels of evidence. The most relevant
international multicenter initiatives and registries include the
PRINTO Registry (a secured web-based registry hosted at the
Pediatric Rheumatology International Trial Organization website
- PRINTO, http://www.printo.it) and EUROFEVER Registry
(an international registry for autoinflammatory diseases, https://
www.printo.it/eurofever/) (15).
Because, by definition, the strength of recommendation
has to be based on a combination of data extracted from
systematic literature review (providing levels of evidence)
and consensus expert opinion (providing homogeneous and
measurable information to generate the recommendations), in
those conditions or situations for which any new therapeutic
information has been reported but no opinion of the experts has
been issued yet, only the level of evidence is mentioned (11, 12).
TRADITIONAL DRUGS
Colchicine
Colchicine is an alkaloid extracted from two plants of the Lily
family: Colchicum autumnale and Gloriosa superba. Historically,
the therapeutic role of colchicine was for the first time raised
up for the treatment of gout in the sixth century (16). More
recently, colchicine use has been extended to other diseases
such as primary biliary cirrhosis, Behçet disease, recurrent
pericarditis, alcohol induced hepatitis, psoriasis, scleroderma,
Sweet syndrome, amyloidosis, sarcoidosis and, in lesser extent,
to inflammatory disorders prone to fibrosis (17–19).
In 1972, the efficacy of colchicine was first described in
five FMF patients who experienced a dramatic reduction of
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TABLE 1 | Categorization of the level of clinical evidence and strength of
recommendation based on the EULAR standardized operating procedures for
EULAR-endorsed recommendations (11, 12).
Category Evidence from
LEVELS OF EVIDENCE
1A Meta-analysis of randomized controlled trials
1B At least one randomized controlled trial
2A At least one controlled study without randomization
2B At least one type of quasi-experimental study
3 Descriptive studies, such as comparative studies, correlation
studies, or case–control studies
4 Expert committee reports or opinions and/or clinical experience of
respected authorities
Grade Directly based on
STRENGTH OF RECOMMENDATION
A Category 1 evidence
B Category 2 evidence or extrapolated recommendation from
category 2 evidence
C Category 3 evidence or extrapolated recommendation from
category 1 or 2 evidence
D Category 4 evidence or extrapolated recommendation from
category 2 or 3 evidence
the number of attacks (20). Since then, colchicine has become
the basis of FMF treatment, and later on, several clinical trials
definitively established its efficacy in preventing attacks and
developing amyloidosis (21–23).
Colchicine was officially approved in 2009 by the US Food
and Drug Administration (FDA) for the acute flares of gout
and FMF, as a single-ingredient oral formulation (Colcrys R©)
(24). Nowadays, according to 2016 EULAR recommendations
for the management of FMF, colchicine represents the first-line
treatment in FMF, with a level of evidence 1B and grade of
recommendation A (13).
Among other biological functions, colchicine has anti-
inflammatory properties based on the inhibition of leukocyte
chemotaxis, which is caused by its interaction with tubulin
and the resulting dysfunction of microtubules. Microtubules,
composed by α- and β-tubulin heterodimers, are involved
in cell division, signal transduction, migration, secretion, and
regulation of gene expression (25). Colchicine has the ability to
bind in a poorly reversible manner to soluble non-polymerized
tubulin in the cells, with the formation of a tubulin–colchicine
complex (26, 27), and the subsequent movement inhibition of
intracellular granules (28).
The predominant effect of colchicine on leukocytes, and
more specific on granulocytes, has been correlated with the
high concentrations of the drug in neutrophils compared to
lymphocytes and monocytes. In this regard, defects in the
efflux pumps with low activity of the P-glycoprotein 1 (PGY-1)
efflux pump of granulocytes might explain the accumulation of
colchicine in their cytoplasm (29, 30).
Other anti-inflammatory effects of colchicine include the
reduction of TNF-α production by macrophages and TNF-α
receptors on endothelial cells and the abrogation of neutrophil
binding to adhesion molecules on vascular endothelium.
Colchicine also decreases phospholipase A2 activity, release of
lysosomal enzymes, and phagocytosis (31–33).
After the discovery of theMEFV gene as the gene encoding for
pyrin and responsible for FMF,MEFV was found fully expressed
in neutrophils, and some authors evidenced a colchicine-
related cytosolic modulation of pyrin expression (34–36). Finally,
colchicine has been shown to suppress the activation of caspase
1, the enzymatic component of NLRP3 inflammasome, with the
subsequent inability to convert pro–IL-1β to active IL-1β (37).
Pharmacokinetic properties of colchicine include a narrow
therapeutic range because the half-life after oral ingestion ranges
between 7 and 9 h. The drug is absorbed in the jejunum and
ileum and is metabolized in the liver by the cytochrome P
(CYP) 450 3A4 and PGY-1. It is finally excreted mainly by
the biliary, intestinal, and renal systems. Colchicine use in
pregnant or nursing patients is considered relatively safe as
long as hepatic and renal functions are intact. In this regard,
because colchicine is metabolized via CYP3A4, its concomitant
administration with agents that inhibit this isoenzyme (e.g.,
macrolide antibiotics, azole antifungals, statins) may produce
elevated colchicine plasma concentrations, resulting in severe,
and sometimes fatal complications. Colchicine intoxication
may be also induced in patients with renal and/or liver
disorders (38, 39).
Colchicine in Autoinflammatory Diseases
Familial Mediterranean Fever
Therapeutic doses of colchicine to treat FMF should be adjusted
to the body weight, with a mean optimal dose of 0.03 ±
0.02 mg/kg per day. Total doses usually range from 0.5 to 2
mg/d in children and from 1 to 3 mg/d in adults (40, 41).
Colchicine usually reduces severity, duration, and frequency of
the attacks in the majority of FMF patients. Among them, ∼30–
40% of individuals experience a partial response (42). After ruling
out any colchicine-associated gastrointestinal intolerance, other
adverse effect, or poor patient compliance, only 5–10% of FMF
cases can be finally considered colchicine-resistant FMF (crFMF)
patients (15, 43).
Intravenous colchicine has shown efficacy in some patients
unresponsive or with partial response to the oral formulation
(43–45). An adjunctive weekly infusion of (1mg) colchicine
in FMF patients with frequent attacks despite a maximum
tolerated oral dosage of 2–3 mg/d was associated with 50%
reduction in frequency of attacks after 6 months (45). However,
because of the potential risk of toxicity, intravenous colchicine is
currently not recommended in FMF patients unresponsive to the
oral formulation.
Other Autoinflammatory Diseases
Colchicine has not demonstrated effectiveness in HIDS/MKD
and CAPS (14, 15). However, it has shown to be somehow
effective in TRAPS and PFAPA syndrome. In the Eurofever
Registry, colchicine was used in 39 TRAPS patients, with
complete and partial response in 3 (8%) and 18 (46%) individuals,
respectively (15). In a recent study of 24 patients with TRAPS,
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colchicine resulted to be of some help in 71% of cases, with a
complete response in 12.5% of them. No differences in colchicine
response were observed with regard to age at disease onset
(pediatric vs. adult), type of variant (low vs. high penetrance),
and colchine daily doses (1mg vs. higher doses) (46). In 303
PFAPA patients from a tertiary Turkish center, colchicine was
used as regular prophylactic treatment with high rate of response
in terms of reduction of the frequency of episodes. Interestingly,
heterozygous mutations in the MEFV gene were found in 25%
of PFAPA subjects, who obtained even better results in terms
of reduction of attacks. The potential modifier role of MEFV
mutations in PFAPA patients seems associated with attenuated
disease severity and higher response rate to colchicine compared
to non-carriers ofMEFV variants (47–49).
Non-steroidal Anti-inflammatory Drugs
The main therapeutic effects of non-steroidal anti-inflammatory
drugs (NSAIDs) are determined by the inhibition of
cyclooxygenases, enzymes that convert arachidonic acid in
prostaglandins, and thromboxanes. Some of these eicosanoids
participate in different pathways involved in the inflammatory
response. However, because NSAIDs do not inhibit the
biosynthetic cascade originating arachidonic acid, these drugs do
not usually influence the underlying cause of the disease.
NSAIDs in Autoinflammatory Diseases
NSAIDs have been used in monogenic autoinflammatory
diseases as symptomatic treatment, alone or in addition to
the baseline therapy. Although a complete response has been
reported in a minority of patients with autoinflammatory
conditions in the Eurofever Registry (8% of FMF and TRAPS,
13% of HIDS/MKD, 6% of CAPS, and 4% of PFAPA patients),
NSAIDs, alone or in combination with glucocorticoids, appear to
be of some help in 70–80% of all cases (15).
In some FMF patients with exertional leg pain and protracted
febrile myalgia, similarly to glucocorticoids, NSAIDs seem to
be also effective (50). Protracted febrile myalgia is a condition
characterized by prolonged episodes of muscle pain affecting
limbs with marked systemic inflammatory response in the
absence of rhabdomyolysis. The EULAR recommendations for
treating this complication with NSAIDs have a level of evidence
2B and grade of recommendation C (13).
Patients with TRAPS associated with R92Q mutations have
been reported to respond better to the combination of colchicine
and NSAIDs than those carrying clearly pathogenic TNFRSF1A
mutations (15, 51). However, in TRAPS, HIDS/MKD, and CAPS
patients, the use of NSAIDs as pain relievers during inflammatory
attacks is recommended with a level of evidence 3 and strength of
recommendation D (for TRAPS) and C (for HIDS/MKD, CAPS,
and PFAPA syndrome) (14, 15).
Glucocorticoids
Glucocorticoids suppress the production and effects of
several proinflammatory mediators, induce the inhibition
of leukocytes migration to the inflammatory foci, and
interfere with the function of fibroblasts and endothelial
cells, thereby exerting a powerful anti-inflammatory action,
both on acute manifestations (i.e., pain, edema) and on late
inflammatory stages (including reparative processes, such as cell
proliferation and fibrosis). Glucocorticoids bind to a specific
intracytoplasmic receptor, a ligand-activated transcription factor
with both positive and negative effects on the regulation of
gene expression. Consequently, the activated glucocorticoid
receptor–glucocorticoid complex up-regulates the expression
of anti-inflammatory proteins and suppresses the transcription
of proinflammatory cytokines and chemokines by blocking the
NF-κB signaling pathway (52).
Glucocorticoids in Autoinflammatory Diseases
Familial Mediterranean Fever
In FMF patients, when colchicine becomes insufficient to control
the disease activity, glucocorticoids (always in combination with
colchicine) have shown positive effects with variable response
in 83% of the 47 cases recruited from the Eurofever Registry
(15). The use of intravenous methylprednisolone (40mg) on
demand has also demonstrated efficacy in decreasing fever and
abdominal and pleuritic pain during attacks in a study of 31 FMF
patients (53).
FMF patients with protracted febrile myalgia may be
controlled with intravenous and/or oral administration of high-
dose glucocorticoids (54). In fact, glucocorticoids have been
recommended for treating this complication with a level of
evidence 2B and grade of recommendation C (13). A recent study
on eight FMF patients with protracted febrile myalgia has shown
good response with the use of intravenous methylprednisolone
pulses, at a dose of 10 mg/kg per day, for 3 days, followed by
oral glucocorticoids, at initial doses of 1–2 mg/kg and gradual
tapering down over 6 weeks (55). A small comparative study on
15 FMF patients with protracted febrile myalgia suggested similar
efficacy of oral glucocorticoids and NSAIDs (50).
Tumor Necrosis Factor Receptor–Associated Periodic Fever
Syndrome
In TRAPS patients, prednisone (or equivalent) may be useful
on demand, administered during the attacks at a dose of 1
mg/kg per day, usually with rapid tapering and cessation in the
following days (51, 56, 57). In the Eurofever Registry, short-
term glucocorticoids, with or without concomitant NSAIDs, were
considered effective for controlling inflammatory attacks in 91%
of TRAPS patients, with complete response in 41% of them (15).
Glucocorticoids do not seem to have any significant effect in
preventing amyloidosis, and its intermittent use does not reduce
either the frequency of attacks or subclinical inflammation
between them. Glucocorticoids in TRAPS are recommended
either as short-term courses or as maintenance treatment with
a level of evidence 3 and strength of recommendation C (14).
As in other monogenic autoinflammatory disorders, some
TRAPS patients may require long-term glucocorticoid therapy.
In these glucocorticoid-dependent situations, a biological agent
is often warranted in order to avoid steroid side effects.
Indeed, almost 80% of TRAPS patients initially treated
with glucocorticoids may finally receive biologic agents as
maintenance therapy to control symptoms (14, 58).
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Hyperimmunoglobulin D Syndrome/Mevalonate Kinase
Deficiency
Similarly to TRAPS patients, in HIDS/MKD, high-dose
glucocorticoids may be useful during the attacks with some
benefit in 73% of cases. However, complete improvement is
achieved by only 9% of patients, and glucocorticoids do not
decrease neither the intensity nor the frequency of the acute
episodes (15). Short-term glucocorticoids, with or without
NSAIDs, may be effective for alleviating inflammatory attacks
and are recommended with a level of evidence 3 and strength of
recommendation C (14).
Cryopyrin-Associated Periodic Syndromes
In CAPS patients, glucocorticoids, mostly used on demand,
resulted in some benefit in 80% of patients included in the
Eurofever Registry. However, glucocorticoids do not control
the underlying inflammatory process or decrease the frequency
of the attacks (15, 59). Anyway, for symptomatic adjunctive
therapy, short courses of NSAIDs and glucocorticoids may be
used, with a level of evidence 3 and strength of recommendation
C (14). However, they should not be used for primary
maintenance therapy (level of evidence 4 and grade of
recommendation D) (14).
PFAPA Syndrome
Glucocorticoids are the treatment of choice in PFAPA syndrome,
because their prompt administration is able to discontinue the
attacks rapidly and completely in the majority of patients. Such
dramatic response is usually considered a peculiar diagnostic
feature in pediatric and adult patients (15, 60–63). The
conventional dosage from 0.5 to 2 mg/kg of prednisone (or
equivalent) in a single dose at the time of fever onset has been
proved useful in a randomized clinical trial (64), and therefore,
glucocorticoids can be recommended in PFAPA patients with
a level of evidence 2B (15). However, additional doses of
glucocorticoids may be occasionally necessary. Their use does
not prevent further attacks and may even be associated with an
increased frequency of the attacks in 25–50% of cases (15, 60).
Of note, the evidence for the effectiveness of tonsillectomy
in children with PFAPA syndrome is based on a systematic
review that included two small randomized controlled trials
studying the effects of tonsillectomy compared to no surgery.
Tonsillectomy was associated with immediate and complete
clinical resolution and significant reduction in the frequency
and severity of symptoms (65). Although these results have to
be interpreted considering the clinical severity, the previous
response to a single dose of prednisone, and the surgical risk in
every individual situation, tonsillectomy as a therapy for PFAPA
syndrome can be recommended with a level of evidence 1A (15).
Other Conventional Agents
Thalidomide
Thalidomide exerts its immunomodulatory and anti-
inflammatory actions through inhibiting TNF-α and
IFN-γ synthesis, leukocyte chemotaxis, and angiogenesis.
Teratogenicity and polyneuropathy are known as the most
feared thalidomide-related serious adverse events. Thalidomide
is an accepted treatment for dermatological diseases (such as
leprous erythema nodosum, severe mucosal ulcers, cutaneous
lupus erythematosus, and chronic graft-vs.-host disease),
refractory multiple myeloma, and other systemic autoimmune or
inflammatory conditions. Evidence on the efficacy of thalidomide
in autoinflammatory diseases is limited to sporadic case reports
and series. In three crFMF patients treated with thalidomide
in addition to colchicine, the combination did not show clear
benefit (66). Similarly, thalidomide failed to demonstrate any
biological or clinical effect in six patients with HIDS/MKD (67).
Dapsone
Dapsone is an antibacterial sulfonamide drug with anti-
inflammatory properties due to the inhibition of function and
chemotaxis of neutrophils and blockade of the inflammatory
effects of multiple prostaglandins and leukotrienes. Dapsone
is currently used for the treatment of different infectious and
immune-mediated systemic and dermatologic conditions (68). In
monogenic autoinflammatory diseases, dapsone has been used in
a case series of 10 crFMF patients with control of attacks in half of
them. The authors postulated that dapsone might be considered
as an alternative therapy in selected FMF cases not responding to
colchicine (68).
Interferon α
The use of IFN-α in patients with FMF resistant to colchicine
has been reported with controversial results. While in several
crFMF cases IFN-α seemed to induce a marked decrease
in both severity and frequency of the attacks, alone or in
combinationwith colchicine (69–72), a double-blind randomized
clinical trial of 22 FMF patients comparing IFN-α with placebo
(without concomitant colchicine) did not demonstrate clear
efficacy of IFN-α in reducing severity of attacks or inflammatory
markers (73).
Other Drugs
Other anti-inflammatory, immune-modulatory, or
immunosuppressive agents, such as azathioprine, methotrexate,
cyclosporine, leflunomide, mycophenolate mofetil, sulfasalazine,
statins, cimetidine, and antihistamines, have been historically
used in monogenic autoinflammatory diseases mostly with
unclear or unsatisfactory results (15, 51).
BIOLOGIC AGENTS
Interleukin 1 Blockers
It is well-known that IL-1 production has strong impact on
initiation and maintenance of inflammatory process. Both IL-
1α and IL-1β bind to the IL-1 receptor type, which is expressed
by nearly every human cell and is responsible for triggering the
cascade of inflammatory processes (74). IL-1 inhibitory molecule
was first described over 30 years ago in the urine from patients
with fever and monocytic leukemia (75, 76). This molecule was
later cloned and identified as IL-1 receptor antagonist (IL-1Ra)
(77), and subsequently, it was hypothesized that the inhibition
of IL-1 with IL-1Ra could be a potential therapeutic option for
treating inflammatory diseases (78).
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TABLE 2 | Anti-IL-1 agents, types of studies supporting the maximum evidence level for their use, and common pediatric and adult doses given in the main monogenic












Anakinra crFMF RCT, RCS No/No 50–300 mg/day 50–100 mg/day (80, 81)
TRAPS OLS, CS No/No 1.5 mg/kg/day 100 mg/day (82, 83)










PFAPA CS, CR No/No 1 mg/kg/day* 100 mg/day* (93, 94)
Canakinumab crFMF RCT, OLS Yes/Yes 2 mg/Kg q4w or q8w 150–300mg q4w or q8w (95–97)
TRAPS RCT, OLS Yes/Yes 2 mg/Kg q4w or q8w 150–300mg q4w or q8w (95, 98)
HIDS/MKD RCT, OLS Yes/Yes 2 mg/Kg q4w or q8w 150–300mg q4w or q8w (95, 99)
CAPS RCT, OLS Yes/Yes 2–10 mg/Kg q4w or q8w 150–300mg q4w or q8w (100–104)
PFAPA CR No/No 2 mg/kg q8w 150mg q8w (105, 106)
Rilonacept crFMF RCT No/No 2.2 mg/Kg qw 160mg qw (107)





*In some cases, on demand administration at the beginning of the febrile episode may also be used.
**Only for CINCA/NOMID cases.
CAPS, cryopyrin-associated periodic syndromes; CINCA/NOMID, chronic infantile neurological, cutaneous and articular syndrome/neonatal onset multisystem inflammatory disorder;
CR, case report; CS, case series; crFMF, colchicine-resistant familial Mediterranean fever; EMA, European Medicines Agency; FDA, Food and Drug Administration; HIDS/MKD,
hyperimmunoglobulin D and periodic fever syndrome/mevalonate kinase deficiency; OLS, open-label study; PFAPA, periodic fever with aphthous stomatitis, pharyngitis and cervical
adenitis; RCS, retrospective cohort study; RCT, randomized controlled trial; TRAPS, TNF-receptor associated periodic fever syndrome.
With regard to inflammasome-mediated autoinflammatory
diseases, such as FMF, TRAPS, HIDS/MKD, and CAPS, IL-1
blockade has become the most specific and useful treatment,
as first-line therapy or when previous conventional anti-
inflammatory or immunosuppressive agents are not useful.
Although several IL-1 blockers are currently under development
(79), the three biologic agents targeting IL-1 with special interest
in autoinflammatory diseases, commercially available nowadays,
are anakinra, canakinumab, and rilonacept.
Table 2 illustrates the most relevant studies supporting the
maximum evidence level for the use of IL-1 blockers in the
main monogenic autoinflammatory diseases (crFMF, TRAPS,
HIDS/MKD, and CAPS) and PFAPA syndrome and includes the
doses used in pediatric and adult patients.
Anakinra
Anakinra is a recombinant non-glycosylated form of the human
IL-1 receptor antagonist (rhIL-1Ra) that binds to IL-1 receptor
type I (IL-1RI) and acts as competitive inhibitor with IL-1α
and IL-1β, in a way that mimics the activity of endogenous
IL-1Ra (110). Anakinra has been approved by the FDA and
EuropeanMedicines Agency (EMA) for rheumatoid arthritis and
by the EMA for the treatment of Still disease, including systemic
juvenile idiopathic arthritis and adult-onset Still disease. In 2012,
anakinra was approved for the treatment of CINCA/NOMID in
theUnited States. In the EuropeanUnion, anakinra was approved
by the EMA for all types of CAPS in 2013.
The recommended initial dose of anakinra is 100 mg/d
subcutaneously in adults and 0.5–2 mg/kg per day in children,
who may require increasing dosage up to 5–8 mg/kg per day to
maintain remission. The need of higher requirements of anakinra
in pediatric patients might be related to pharmacokinetics of
the drug whose effective steady-state concentration in young
children seems to be higher than in adults (14, 111). Anakinra
terminal half-life ranges from 4 to 6 h, and ∼80% of the drug
is excreted by renal clearance (112). Consequently, the mean
plasma clearance of the drug strongly depends on normal
kidney function, and anakinra removal from plasma is minimally
feasible through dialysis (113).
An animal study showed that up to two-thirds of serum
IL-1Ra are able to cross blood–brain barrier. On clinical
grounds, anakinra administration has determined improvement
of memory and cognitive functions in CAPS patients (85, 114).
Safety data on anakinra comes from rheumatoid arthritis
randomized controlled trials and long-term observational
studies, in which good safety profiles have been observed with
no increase of opportunistic infections or malignancies (141,
142). Data from the British Society of Rheumatology Biologic
Register reported higher rates of serious infections of the skin and
respiratory tract in subjects with more severe disease and higher
exposure to glucocorticoids (143). The increased susceptibility
to respiratory infections in patients treated with anti–IL-1 might
be explained by the fact that IL-1β seems to play a role in the
resistance to Streptococcus pneumoniae infection (144). Although
the most frequent adverse event by far of anakinra is the
injection site skin reaction, which is observed in up to 70% of
patients, this local reaction tends to decline over time without the
need of treatment discontinuation (145). Anakinra use during
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pregnancy has not been associated with an increased rate of
miscarriages or congenital malformations, neither in a registry
of 40 patients (146) nor in small series of FMF and CAPS
patients (147, 148).
Canakinumab
Canakinumab is a fully humanized IgG1 monoclonal antibody
that acts specifically against IL-1β. In 2009, canakinumab
received the FDA approval for CAPS treatment, specifically for
FCAS and MWS, and EMA approval for children older than 2
years and adults with all forms of CAPS. More recently, in 2016,
the FDA and EMA approved canakinumab for the treatment of
crFMF, TRAPS, and MKD, based on the results of the phase
3 Canakinumab Pivotal Umbrella Study in Three Hereditary
Periodic Fevers (CLUSTER) trial (95). Additional indications
of canakinumab include systemic juvenile idiopathic arthritis
(by the FDA) and Still disease (systemic juvenile idiopathic
arthritis and adult-onset Still disease) and gouty arthritis
(by the EMA).
Given its long half-life of 26 days, canakinumab
administration is recommended subcutaneously at 2–4 mg/kg
in children and at a minimal dose of 150mg in adults, every
4–8 weeks in both age groups. Patients with more severe
phenotypes may require dose escalation. For instance, patients
with CINCA/NOMID (the most severe CAPS phenotype) may
require up to 8 mg/kg dosage every 4 weeks to control symptoms
(100, 101). Similarly, in crFMF, TRAPS, and MKD patients, the
recommended starting dose is usually 150mg or 2 mg/kg (in
children with body weight between 7.5 and 49 kg) every 4 weeks,
with the possibility to increase up to 300mg every 4 weeks (or
4 mg/kg in children), which is more often required by MKD
patients (95).
Its penetrance of the blood–brain barrier seems incomplete
because canakinumab does not normalize intrathecal
inflammatory markers, as demonstrated in two case series
of CINCA/NOMID patients (149, 150). Renal function does not
influence the pharmacokinetics of canakinumab (151). Data on
pregnancy and breastfeeding are still scarce. However, seven of
eight pregnancies of patients on canakinumab were reported
uneventful, and no developmental abnormalities were reported
in four breastfed infants while mothers were on canakinumab
treatment (152).
Mild infections, involving mostly the urinary tract and upper
airway, represent the most frequent canakinumab-associated
adverse events. However, serious infections have been reported
in 5.4/100 patients-years in 285 patients included in the long-
term CAPS registry (153) and in 7.4/100 patients-years of
FMF, TRAPS, and MKD patients treated with higher doses of
canakinumab in the CLUSTER trial (95).
Additional data on safety can be extrapolated from
the randomized, double-blind, placebo controlled trial of
canakinumab in patients with atherosclerotic disease, with more
than 10,000 individuals and ∼30% of them receiving placebo
(154). Neutropenia and thrombocytopenia were observed in the
treatment group, with more deaths attributed to infections or
sepsis, however, with no statistically significant differences in the
overall rates of adverse events compared with placebo (154).
Rilonacept
Rilonacept is a dimeric fusion glycoprotein consisting of the
Fc portion of human IgG1 and the human IL-1 receptor
extracellular domains that binds IL-1α and IL-1β. In 2008,
rilonacept was the first agent approved by the FDA for the
treatment of FCAS and MWS in patients older than 12 years,
based on two sequential phase III clinical studies, which
demonstrated rilonacept safety and effectiveness in adult patients
with CAPS (108). Rilonacept obtained a marketing authorization
only in the United States.
Initial dose in adults is recommended at 320mg
subcutaneously, followed by a weekly dose of 160mg. In
children older than 11 years and adolescents, the dose has to be
adjusted at 4.4 mg/kg (maximum of 320mg) and then 2.2 mg/kg
(maximum of 160mg) once weekly. The circulating half-life may
vary from 6 to 9 days (155, 156). Being a large molecule, it is
expected not to cross the blood–brain barrier and to be cleared
primarily by the reticuloendothelial system rather than by the
kidney. Therefore, a dose adjustment in patients with renal
disease is not required (157).
Injection site reactions, headache, and upper respiratory
tract and urinary infections have been described as the most
common adverse events in CAPS patients treated with rilonacept
(109). Data from studies and trials on gout and gouty arthritis
suggest also that several laboratory changes may occur, including
transient neutropenia and a small increase in liver transaminases,
triglycerides, and creatine phosphokinase (158).
IL-1 Blockers in Autoinflammatory Diseases
Familial Mediterranean Fever
IL-1 blockade with anakinra is currently recommended for FMF
in case of true colchicine resistance, with a level of evidence 2B
and strength of recommendation B, and as an optional treatment
for protracted febrile myalgia, with a level of agreement 2B and
grade of recommendation C (13).
Although in 2011 the Eurofever Registry included only
three FMF patients treated with anakinra with complete
response (15), a 2013 literature review identified 30 FMF cases
resistant or intolerant to colchicine treated with anakinra, and
four with canakinumab, with good clinical and laboratory
outcomes (110). A 2015 systematic review reported 64 patients
treated with anakinra and 40 with canakinumab. A complete
response without attacks occurred in 76.5 and 67.5% of
patients on anakinra and canakinumab, respectively. In patients
with established type AA amyloidosis, both anti–IL-1 agents
demonstrated to reverse proteinuria (159). Anakinra has been
administered on demand with efficacy to some selected crFMF
patients, mainly those with prominent prodromal manifestations
or recognizable triggers of the attacks (160).
Ben-Zvi et al. (80) enrolled 25 adult patients with crFMF
in the first double-blind randomized placebo-controlled trial,
aiming to assess efficacy and safety of anakinra at a dose of
100 mg/d during 4 months of treatment. Adult FMF patients
experiencing at least one attack per month despite the maximum
tolerated dose of colchicine (up to 3mg/d) were enrolled. Patients
treated with anakinra had an attack rate of 1.7 per month,
whereas those receiving placebo suffered 3.5 attacks per month.
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In addition, anakinra was associated with better quality of life,
and no differences in the development of adverse effects were
found. Interestingly, the best results with anakinra were observed
in terms of amelioration of joint manifestations (80). In a Turkish
multicenter retrospective study of 172 crFMF patients, in whom
151 were treated with anakinra and 21 with canakinumab, both
drugs reduced the yearly attack frequency from 16.8 to 2.4 (p
< 0.001). Forty-two percent of crFMF patients were attack-free,
and proteinuria was significantly reduced in those patients with
amyloidosis (81).
Canakinumab has proved effective in several retrospective
FMF reviews (161–163) and two open-label phase II studies
with nine and seven crFMF patients (96, 97). Both phase II
trials established the efficacy of canakinumab in reducing the
frequency of FMF attacks and maintaining low levels of acute
phase reactants, with no unexpected adverse events (96, 97). The
recent FDA and EMA approval of canakinumab for patients with
FMF resistant or intolerant to colchicine has been based on data
from the CLUSTER trial (95).
A total of 63 patients with crFMF were randomized to receive
canakinumab 150mg or placebo every 4 weeks. At week 16,
canakinumab compared with placebo produced a significantly
higher response rate by day 15 (61 vs. 6%), higher rates of
physician global assessment of disease activity (minimal/none)
(65 vs. 9%), and higher C-reactive protein (CRP) levels≤10mg/L
(68 vs. 6%) and serum amyloid A (SAA) levels ≤10 mg/L (65 vs.
9%) (95). Canakinumab also demonstrated a rapid and sustained
disease control assessed with the Autoinflammatory Disease
Activity Index (AIDAI) over 16 weeks, and approximately half of
crFMF patients had inactive disease after the same period (164).
In the open-label phase from weeks 16–40, all FMF patients with
a previous complete response to canakinumab 150mg every 4
weeksmaintained the absence of flares with canakinumab 150mg
every 8 weeks. After that period, the same dose interval of every
8 weeks was sufficient to maintain disease control in 46% of
patients. An increase in the dose to 300mg every 4 weeks was
required by 10% of crFMF patients (95).
Adverse events and serious adverse events were more frequent
in canakinumab-treated patients than in those receiving placebo.
Overall, the most frequently reported adverse events were
infections (mostly those affecting the respiratory tract), headache,
abdominal pain, and injection-site reactions. Rates of infections
and serious infections were of 173.3 and 6.6 per 100 patient-years
of treatment, respectively (95).
With regard to rilonacept, this agent was administered
to 14 FMF patients with one or more attacks per month
in a randomized double-blind, single-participant alternating
treatment study, with a significant reduction in the number of
FMF attacks. Injection site reactions were the only adverse events
associated to rilonacept administration (107).
Tumor Necrosis Factor Receptor–Associated Periodic Fever
Syndrome
Anti–IL-1 agents have demonstrated efficacy in the majority of
TRAPS patients. Anakinra seems to be superior to etanercept
in retrospective TRAPS studies (15). In the Eurofever Registry,
anakinra provided some benefit in ∼90% of TRAPS patients,
with a complete remission in 67% of them (15). Anakinra
has shown to be effective, both in continuous and on-demand
administration (14, 15, 57, 82, 83, 165), and is recommended
in TRAPS patients with a level of evidence 2B and strength of
recommendation B (14).
Canakinumab induced a complete response in 19 of 20 TRAPS
patients in an open-label, phase II study (98), but it has been
recently labeled by the FDA and EMA for TRAPS patients based
on data from the CLUSTER trial (95). In such trial, among the
46 TRAPS patients randomized to receive canakinumab 150mg
or placebo every 4 weeks, at week 16, canakinumab, compared
to placebo, was associated with a higher response rate by day
15 (45 vs. 8%), higher rates of (minimal/none) physician global
assessment of disease activity (45 vs. 4%), and higher CRP levels
≤10 mg/L (36 vs. 8%) and SAA levels ≤10 mg/L (27 vs. 0%)
at week 16. Canakinumab also produced a rapid and sustained
disease control assessed with AIDAI over 16 weeks, and about
half of TRAPS patients had inactive disease after the same period
(164). In the open-label phase from week 16–40, 83% of TRAPS
patients with a previous complete response to canakinumab
150mg every 4 weeks maintained the absence of flares with
canakinumab 150mg every 8 weeks. After that period, the same
dose interval of every 8 weeks was sufficient to maintain disease
control in 53% of patients. An increase in the dose to 300mg
every 4 weeks was required by 8% of TRAPS patients (95).
Similarly to FMF patients of the CLUSTER study, TRAPS
patients treated with canakinumab developed more frequently
adverse events and serious adverse events than patients receiving
placebo. The rate of infections was of 148 per 100 patient-years of
treatment, and no serious infections were observed (95).
Hyperimmunoglobulin D Syndrome/Mevalonate Kinase
Deficiency
In HIDS/MKD, anakinra, and canakinumab may control or
attenuate the intensity of attacks in most of patients. In the
Eurofever Registry, among the 62 HIDS/MKD patients treated
with anakinra, 84% obtained a positive response, which was
complete in only 29% of them (15). On-demand administration
of anakinra in HIDS/MKD patients decreases the duration
and severity of symptoms attacks when started within 24 h
after the onset of symptoms. However, on-demand regimen
does not influence the frequency of attacks (84). Anakinra is
recommended for treating HIDS/MKD patients with a level of
evidence 2B and strength of recommendation C (14).
Efficacy and safety of canakinumab have been recently
investigated in an open-label phase II study in nine patients (six
pediatric and three adults) with HIDS, using a predefined dosage
of 300mg or 4 mg/kg for patients ≤40 kg (higher than the usual
dose of 150mg used in CAPS), with an interval administration
of every 6 weeks (99). A significant reduction of attacks
frequency and complete clinical response with normalization of
inflammatory markers within the first month of treatment were
noted in all patients (99).
As for crFMF and TRAPS, canakinumab has also been recently
approved by the FDA and EMA for HIDS/MKD treatment,
based on the data derived from the CLUSTER trial (95). Among
the 72 HIDS/MKD patients included in the study (treated with
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canakinumab 150mg or placebo every 4 weeks), those receiving
canakinumab experienced better response rate by day 15 (35 vs.
6%), higher rates of (minimal/none) physician global assessment
of disease activity (46 vs. 6%), and higher CRP levels ≤10
mg/L (41 vs. 6%) and SAA levels ≤10 mg/L (41 vs. 6%) at
week 16. Canakinumab was also associated with a rapid and
sustained disease control assessed with AIDAI over 16 weeks,
and 40% of HIDS/MKD patients had inactive disease after the
same period (164). In the open-label phase from week 16–40,
82% of HIDS/MKD patients with a previous complete response
to canakinumab 150mg every 4 weeks maintained the absence
of flares with canakinumab 150mg every 8 weeks (95). After
that period, the same dose interval of every 8 weeks maintained
the disease controlled in only 23% of patients. An increase
in the dose to 300mg every 4 weeks was required by 29%
of patients (95).
Similarly to FMF and TRAPS patients, in HIDS/MKD patients
of the CLUSTER study, adverse events and serious adverse
events were more frequent in patients treated with canakinumab
than with placebo. Rates of infections and serious infections
in HIDS/MKD were of 313.5 and 13.7 per 100 patient-years
of treatment, which were higher than for FMF and TRAPS
patients (95).
Cryopyrin-Associated Periodic Syndromes
Anakinra, canakinumab, and rilonacept are approved by the
FDA and EMA for CAPS treatment. All the three anti–IL-
1 agents are currently recommended as first-line therapy in
CAPS patients of any age, with a level of evidence 1B for
canakinumab and rilonacept, and 2A for anakinra, and a strength
of recommendation A and B, respectively (14).
Anakinra has demonstrated to control clinical and biological
activity in CAPS. FDA approval of anakinra was based
on a long-term, open-label, and uncontrolled study of 18
CINCA/NOMID patients, in whom symptoms and inflammatory
markers improved in all of them (86). This study provided
relevant information about dosage variability of anakinra to
control CAPS activity. Patients were treated with an initial dose
of 1–2.4 mg/kg body weight and an average maintenance dose
of 3–4 mg/kg per day (with a maximum dose administered
of 7.6 mg/kg per day). Although most of individuals received
a single daily dose, some of them achieved better control of
disease by splitting the dose into two daily administrations. Upon
withdrawal of treatment, disease flare occurred after a median
time of 5 days (86).
Several open-label and prospective studies (85–90) and
retrospective series (91, 92) supported EMA approval of anakinra
in adults and pediatric patients 8 months or older with a body
weight of 10 kg or greater, diagnosed with any type of CAPS
[CINCA/NOMID (85, 86, 91, 92), MWS (85, 87, 88), and
FCAS (88–90)].
Although anakinra does not seem to control the progression
of osteoarticular deformities in CINCA/NOMID patients (166,
167), it improves leptomeningeal and cochlear involvement,
due to its ability to penetrate the blood–brain barrier (15, 168,
169). Therefore, anakinra appears to be more effective than
canakinumab in the intrathecal compartment (149).
Anakinra efficacy and safety were analyzed in a prospective,
open-label, single-center clinical cohort study, including 43
severe CAPS patients followed during a mean of 5 years (170).
Anakinra was safe and well-tolerated both in pediatric and adult
patients, with most adverse events emerging during the first
months after treatment initiation. The most frequent adverse
events included headache, arthralgia, and injection site reactions.
Infections, such as pneumonia and gastroenteritis, occurred
in ∼25% of patients, but they did not require permanent
discontinuation of treatment. Interestingly, an increase of
anakinra dose was required in two cases during an infectious
event with a concomitant disease flare (170).
Canakinumab induced clinical and biological remission in
75–90% of CAPS patients in the Eurofever Registry (15). The
approval of canakinumab for CAPS was based on a 48-week,
double-blind, placebo-controlled trial of 35 patients with CAPS
(mainly MWS patients) treated with 150mg every 8 weeks, in
which 97% of patients had a complete response to canakinumab
during the study period (102). In addition, another randomized
controlled trial (103) and two observational studies on CAPS
patients including all disease phenotypes similarly showed good
results (100, 104).
A prospective study comparing the efficacy and safety of
canakinumab and anakinra in 26 MWS patients concluded
that both agents equally controlled disease activity and
inflammatory markers and that canakinumab may be
effective in some patients not responding to anakinra (104).
Occasionally, patients receiving anakinra and those treated
with canakinumab (mainly CINCA/NOMID patients) may
require an increase of dose or frequency of administration of the
drug (101, 104).
Rilonacept showed efficacy in 47 adult patients with CAPS (44
with FCAS and 3 with MWS) in a randomized controlled trial
and in an extended open-label study of up to 96 weeks including
101 patients with favorable safety and tolerability profile in adult
and pediatric patients (108, 109).
PFAPA Syndrome
Although genetic and pathogenic mechanisms of PFAPA
syndrome are unknown, in a case report and a small cohort of five
PFAPApatients resistant to glucocorticoids, the administration of
anakinra has been effective in suppressing disease flares during
the long-term follow-up (93, 94). Similarly, a pediatric case and
an adult case of PFAPA syndrome have been reported to respond
to canakinumab at a dose of 2 mg/kg and 150mg every 8 weeks,
respectively (105, 106).
TNF Blockers
Anti-TNF agents, mainly etanercept (a dimeric human TNF
receptor p75-Fc fusion protein), infliximab (a chimeric
monoclonal antibody against TNF-α), and adalimumab
(a fully human monoclonal antibody against TNF-α),
have been used in different monogenic autoinflammatory
inflammasomopathies, generally with poorer efficacy than
IL-1 blockers. These biologic agents have been approved for
several autoimmune/inflammatory conditions. Etanercept has
FDA and EMA indications for rheumatoid arthritis, juvenile
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idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis,
and plaque psoriasis; infliximab was approved by the FDA
and EMA for rheumatoid arthritis, ankylosing spondylitis,
psoriatic arthritis, plaque psoriasis, Crohn disease, and
ulcerative colitis, and adalimumab is indicated by the FDA
and EMA for all the previous diseases (approved for etanercept
and infliximab) plus non-infectious uveitis. In addition,
the FDA approved adalimumab as therapy for hidradenitis
suppurativa (acne inversa). None of the anti-TNF drugs have
been approved by either the FDA or EMA for any of the
monogenic autoinflammatory diseases.
TNF Blockers in Autoinflammatory Diseases
Familial Mediterranean Fever
In FMF, the experience with anti-TNF agents has been overall
scarce and unclear. Two small series of 10 and 14 patients
with crFMF and concomitant inflammatory conditions (chronic
arthritis, ankylosing spondylitis, juvenile idiopathic arthritis,
psoriasis, or Crohn disease) treated with all the three TNF
blockers resulted in good control of FMF and the associated
disease (115, 116). Retrospective data included in the Eurofever
Registry showed complete and partial response with etanercept
(in seven and nine cases, respectively), infliximab (seven with
complete and eight with partial response), and adalimumab
(three with complete and two with partial response) (15).
Similarly to the previous series, in this registry, anti-TNF agents
seemed also to exert more benefit in cases with predominant
arthritis (15). In a multicenter international retrospective study
including 27 FMF patients treated with biologic agents, two
patients received adalimumab and two etanercept as first
agent. While one patient experienced a complete response, the
remaining three had to discontinue the drug due to lack of
efficacy after a mean duration of therapy of 9.3 months (117).
The level of evidence of the efficacy of anti-TNF agents in crFMF,
especially in those with articular involvement, is 3, but no grade
of recommendation has been provided (13).
Tumor Necrosis Factor Receptor–Associated Periodic Fever
Syndrome
In TRAPS, etanercept is the anti-TNF agent with the best
reported results, because it has shown to prevent or reduce the
intensity of attacks and the dose of glucocorticoids previously
controlling disease activity (15, 117). However, it is relatively
common that etanercept has to be discontinued because of lack
of efficacy (15, 117), which has been reported after a period
of 3.3 years (118). Although SHARE consensus recommends
etanercept in some patients with a level of evidence 2B and grade
of recommendation C, the experts also inform that the effect
might decline over time (14).
In the Eurofever Registry, among 121 TRAPS patients treated
with etanercept, 88% experienced a satisfactory response, which
was complete in 26% of them (15). A multicenter international
retrospective study including 47 TRAPS patients, 41 with
pathogenic mutations and 6 with the R92Q variant, analyzed
20 and 4 patients treated with etanercept in each group,
respectively. Among TRAPS caused by pathogenic mutations,
∼50% of those receiving etanercept could achieve a complete
clinical response. In addition, a total of 13 of 20 (65%) TRAPS
patients discontinued anti-TNF, mostly due to a lack of efficacy.
Compared to patients receiving anakinra, those treated with
etanercept experienced less frequently a complete response and
higher drug discontinuation rates (117). With regard to the four
R92Q-TRAPS patients receiving etanercept as first-line therapy,
only one (25%) had a complete response (117). Etanercept has
also been reported effective in isolated TRAPS patients carrying
the R92Q variant (57).
The use of infliximab and adalimumab has been associated
with severe paradoxical reactions, and therefore, they are
currently not recommended in TRAPS. While etanercept is a
receptor fusion protein, infliximab, and adalimumab are TNF
monoclonal antibodies. One of the proposed mechanisms by
which infliximab is involved in a hyperinflammatory response is
related to the failure in shedding infliximab-bound receptor from
the cell surface, with the subsequent activation of antiapoptotic
mechanisms and a widespread inflammatory response (171).
Hyperimmunoglobulin D Syndrome/Mevalonate Kinase
Deficiency
In HIDS/MKD, anti-TNF therapy can improve frequency and
intensity of attacks. However, because anti–IL-1 agents can be
considered the first-line therapy for HIDS/MKDpatients (14, 95),
TNF blockers are recommended as a second option (together
with IL-6 blockade) in case of IL-1 blockers are ineffective
or not tolerated, with a level of evidence 4 and grade of
recommendation D (14).
In the Eurofever Registry, etanercept was the most frequently
used anti-TNF drug, providing any improvement in 26 of
44 (59%) of HIDS/MKD patients, which was complete in
seven (16%) of them (15). A multicenter retrospective study
of eight HIDS/MKD patients treated with etanercept showed
higher complete response rates (88%). However, etanercept was
discontinued in four patients (50%) due to lack of efficacy (117).
Cryopyrin-Associated Periodic Syndromes
No evidence of efficacy of biological therapy (including anti-
TNF agents) other than IL-1 blockade in CAPS patients is
available (119).
PFAPA Syndrome
To date, no PFAPA cases treated with anti-TNF agents have
been reported.
Anti–IL-6 Agents: Tocilizumab
Tocilizumab is a humanized monoclonal anti–IL-6 receptor
antibody currently labeled by the FDA and EMA for rheumatoid
arthritis, systemic and polyarticular juvenile idiopathic arthritis,
giant cell arteritis and for the treatment of chimeric antigen
receptor T cell–induced severe or life-threatening cytokine
release syndrome. Tocilizumab has not been approved for
any of the monogenic autoinflammatory diseases because the
experience of its use, usually in patients unresponsive to other
biologic agents, is still occasional.
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TABLE 3 | Biological agents (other than IL-1 blockers), types of studies supporting the maximum evidence level, and response to treatment of the main monogenic
autoinflammatory diseases (crFMF, TRAPS, HIDS/MKD, and CAPS)*.







crFMF RCS Partial or complete response in few patients. Better efficacy in patients with
articular involvement
(15, 115, 116)
TRAPS** RCS Good response in 88% of patients, complete in 25–50% of them (15, 117, 118)
HIDS/MKD RCS Good response in 59–88% of patients, complete in 16% of them
Lack of efficacy over time
(15, 117)
CAPS CR No response (119)
Anti- IL-6
Tocilizumab
crFMF RCS, CS, CR Good response in patients resistant to colchicine, anti-IL-1, and anti-TNF agents (120–128)
TRAPS CR Good response in patients refractory to anti-TNF and anti-IL-1 agents (129–131)
HIDS/MKD CR Good response in patients refractory to anti-TNF and anti-IL-1 agents (132–136)
CAPS CR No response (119, 137)
JAK-inhibitors
Tofacitinib
crFMF CR, CS Good response in patients refractory to anti-TNF, anti-IL-1, and anti-IL-6 agents (138–140)
*No evidence about the use of these drugs in PFAPA syndrome.
**Infliximab and adalimumab are not recommended in TRAPS since their use has been associated with severe paradoxical reactions.
CAPS, cryopyrin-associated periodic syndromes; CR, case report; CS, case series; crFMF, colchicine-resistant familial Mediterranean fever; HIDS/MKD, hyperimmunoglobulin D and
periodic fever syndrome/mevalonate kinase deficiency; IL, interleukin, JAK, Janus kinase; PFAPA, periodic fever with aphthous stomatitis, pharyngitis and cervical adenitis; RCS,
retrospective cohort study; TNF, tumor necrosis factor; TRAPS, TNF-receptor associated periodic fever syndrome.
Tocilizumab in Autoinflammatory Diseases
Familial Mediterranean Fever
Tocilizumab has been successful in controlling disease activity in
the majority of patients with crFMF reported as single cases, with
good control of secondary amyloidosis in some of them (120–
125). Tocilizumab effects over proteinuria in FMF-associated
amyloidosis has been analyzed in two series of 11 and 12
patients resistant to colchicine, anti–IL-1, or anti-TNF agents, in
whom the previous colchicine therapy wasmaintained (126, 127).
Proteinuria improvement in any degree was achieved by 7 of 11
patients (64%) and 9 of 12 patients (75%), respectively (126, 127).
In two of the responder patients, tocilizumab was discontinued,
and proteinuria returned, with good control after restarting IL-6
blockade (128).
Other Autoinflammatory Diseases
Tocilizumab has been successfully used in three patients with
TRAPS (129–131) and in seven HIDS/MKD cases (132–136)
in whom anti-TNF and/or anti–IL-1 agents had previously
failed. Negative results have been reported in two CAPS
(CINCA/NOMID) patients treated with tocilizumab (119, 137).
No evidence on the use of tocilizumab in PFAPA syndrome is
currently reported.
JAK Inhibitors
JAK inhibition suppresses the constitutive phosphorylation of
the transcription factor STAT-1, which blocks the induction of
IFN-stimulated genes and subsequently leads to the regulation
of the uncontrolled IFN production, causing inflammatory
manifestations. Janus kinase inhibitors, such as tofacitinib,
baricitinib, and ruxolitinib, are currently approved by the FDA
and EMA for rheumatoid arthritis, psoriatic arthritis, and
ulcerative colitis (tofacitinib), rheumatoid arthritis (baricitinib),
and myelofibrosis and polycythemia vera (ruxolitinib, also
approved for steroid-refractory acute graft-vs.-host disease by
the FDA).
JAK inhibitors have demonstrated positive effects in several
monogenic autoinflammatory diseases mediated by type
I IFN (also named interferonopathies), including chronic
atypical neutrophilic dermatosis with lipodystrophy and
elevated temperature/proteasome-associated autoinflammatory
syndrome, STING-associated vasculopathy with onset in
infancy, familial chilblain lupus, and Aicardi–Goutières
syndrome (172–175).
Because the pathogenic mechanism of the diseases included
in this review consists mainly in the abnormal function of
the inflammasome, as expected, the use of JAK inhibitors in
monogenic inflammasomopathies remains anecdotal and limited
to six crFMF patients previously failing to IL-1, TNF, and IL-
6 blockers. However, interestingly, these cases were successfully
treated with tofacitinib (138–140).
Table 3 summarizes all the biological agents (other than IL-1
blockers) used in themainmonogenic autoinflammatory diseases
and PFAPA syndrome, and types of studies supporting the
maximum evidence level for their use.
PROPOSAL OF A PRACTICAL GUIDE FOR
TREATING THE MAIN MONOGENIC
AUTOINFLAMMATORY DISEASES AND
PFAPA SYNDROME
Based on the maximum level of evidence and grade of
recommendation for FMF, CAPS, TRAPS, HIDS/MKD,
and PFAPA syndrome, a proposed practical scheme for
the treatment of these conditions is illustrated in Figure 1.
Evidence-based recommendations for the treatment of the
main monogenic autoinflammatory diseases have been
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FIGURE 1 | Proposed approach for the treatment of the main monogenic autoinflammatory diseases and PFAPA syndrome, based on the maximum level of evidence
and grade of recommendation (when available) for each drug and disease.
No strength of recommendation is provided when expert opinion consensus still does not exist.
Thalidomide and dapsone have also been reported of benefit in some colchicine-resistant FMF patients (data within the text).
*This drug has been proved effective with continuous and on demand administration.
**This drug is recommended mostly in short courses (on demand) during attacks.
¦Colchicine in PFAPA patients has been reported more effective in carriers of heterozygous variants in the MEFV gene.
§Anti-TNF agents (etanercept, infliximab, and adalimumab) have been shown more useful in FMF patients with prominent articular manifestations.
#Tocilizumab has been used with efficacy in few patients with FMF, TRAPS, and HIDS/MKD who failed to anti–IL-1 and/or anti-TNF agents.
#Tofacitinib has shown good response in few patients with colchicine-resistant FMF who also failed to IL-1, TNF, and IL-6 blockers.
CAPS, cryopyrin-associated periodic syndrome; FMF, familial Mediterranean fever; HIDS/MKD, hyperimmunoglobulin D and periodic fever syndrome/mevalonate
kinase deficiency; PFAPA, periodic fever with aphthous stomatitis, pharyngitis and cervical adenitis; TRAPS, TNF receptor–associated periodic syndrome.
extracted from previous consensus studies, such as the
EULAR recommendations for the management of FMF
(13) and the European SHARE recommendations for the
management of TRAPS, HIDS/MKD, and CAPS (14).
Additional information used to generate levels of evidence
has been incorporated mostly from results of new clinical
trials, international multicenter registries, and retrospective
data mainly from referral centers. According to the EULAR
standard operating procedures for developing best practice
to endorse recommendations, only the level of evidence is
provided in those diseases with new therapeutic information
but without recommendations issued by consensus expert
opinion (11, 12).
The proposed therapeutic approach includes three different
levels or situations: (a) first-line treatment (at the time of
disease diagnosis or when symptomatic treatment used formilder
situations is not effective); (b) milder cases or special clinical
situations (including severe serositis or protracted febrile myalgia
in case of FMF, or symptomatic treatment inmilder presentations
for the remaining conditions); and (c) second-line treatment
(in case of patients not responding to first-line drugs or other
biologic agents).
STILL UNSOLVED AND OPEN QUESTIONS
Despite the great efforts and progresses achieved during the last
years in the treatment of monogenic autoinflammatory diseases,
several questions remain still pending to be answered:
• how to define resistance or failure to any biologic drug?
• how to demonstrate the effect of biologic agents in preventing
secondary amyloidosis?
• which is the right therapeutic window to initiate or switch to a
biologic agent?
• which biological agent should be used as first?
• when it is time to switch to another biologic agent, and
which biologic?
• how to identify the right moment to start on-demand
treatment and when changing from continuous to on demand
administration is appropriate?
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• how to establish, if possible, reduction and discontinuation of
any treatment used?
NEW TREATMENT STRATEGIES IN
AUTOINFLAMMATORY DISEASES
It is of crucial importance to maintain and boost the
international collaboration with patients’ registries for all the
autoinflammatory diseases and also to promote initiatives that
allow the generation of genetic, clinical, and therapeutic research.
The latter should include drug development in preclinical
(phases I and II) trials, whereas phase III trials (evaluating
safety) should be now focused on testing new drugs and also
on performing head-to-head comparisons between the current
biologic agents, respectively.
With regard to preclinical trials, because the abnormal
activation of the NLRP3 inflammasome seems to be
implicated in conditions other than autoinflammatory diseases,
such as diabetes, atherosclerosis, and cardiovascular and
neurodegenerative diseases, several in vitro and in vivo studies
are exploring the potential role of different pharmacological
inhibitors of the NLRP3 inflammasome in NLRP3-associated
diseases (176). While some of these new agents are small
molecule inhibitors directly acting on the NLRP3 protein,
others are targeting different components and products of the
inflammasome. These new agents include glyburide, 16673-34-0,
JC124, FC11A-2, parthenolide, VX-740, VX-765, Bay 11-7082,
BHB, MNS, CY-09, OLT1177, oridonin, MCC950, and tranilast
(176). Among them, tranilast and other small molecules, such
as IZD174 and IZD334 (related to MCC950), are being used in
patients with CAPS, in phases I and II clinical trials.
Currently, the efficacy and safety of alternative biologic drugs
and small molecules are being studied or pending of results in
several ongoing clinical trials, including:
1) Tocilizumab for the treatment of FMF—a randomized,
double-blind, phase II proof-of-concept study
(ClinicalTrials.gov identifier: NCT03446209). This trial
will analyze the efficacy of tocilizumab in adult patients with
crFMF, also failing to other biologic agents.
2) A randomized, double-blind, parallel-group comparison trial
of tocilizumab for colchicine-resistant FMF (UMIN-CTR
Clinical Trial ID: UMIN000028010). This (phase III) trial will
analyze the efficacy of tocilizumab in patients from 12 to 75
years with crFMF (177).
3) An open-label continuation trial of tocilizumab for FMF with
colchicine ineffective or intolerance (UMIN-CTR Clinical
Trial ID: UMIN000032557). This trial is expected to obtain
evidence regarding the long-term safety of tocilizumab in
crFMF patients (178).
4) Safety and tolerability, pharmacokinetic, and
pharmacodynamic study with IZD334 (ClinicalTrials.gov
identifier: NCT04086602). This is the first-in-human,
single-center, double-blind, randomized, crossover (phase I)
study of IZD334 (a small molecule inhibitor of the NLRP3
inflammasome) conducted in healthy adults as well as an
open-label cohort in adult patients with CAPS.
5) Safety and tolerability, pharmacokinetic, and
pharmacodynamic study with inzomelid (ClinicalTrials.gov
identifier: NCT04015076). A phase I, randomized,
double-blind, placebo-controlled, single- and multiple-
ascending-dose study to determine the safety, tolerability,
pharmacokinetics, pharmacodynamics, and food effect
of inzomelid (or IZD174, a small molecule inhibitor of
the NLRP3 inflammasome) in healthy adult participants,
as well as an open-label cohort to confirm the safety,
pharmacokinetics, and pharmacodynamics of inzomelid in
adult patients with CAPS.
6) A clinical study of tranilast in the treatment of CAPS
(ClinicalTrials.gov identifier: NCT03923140). A single-arm
prospective cohort (phase II) study designed to observe the
efficacy and safety of tranilast (a small molecule inhibitor of
the NLRP3 inflammasome) in CAPS patients.
7) Ilaris R© (canakinumab) in PFAPA patients (ClinicalTrials.gov
identifier: NCT02775994). This single-arm open-label pilot
study will analyze the efficacy of canakinumab during the first
2 months of treatment in 10 children with PFAPA syndrome
experiencing frequent flares.
CONCLUDING REMARKS
• Colchicine, used at therapeutic doses, is the criterion-standard
treatment for FMF and of some help in PFAPA patients, mostly
in those carrying heterozygousMEFV gene mutations.
• NSAIDs improve symptoms in most patients with any
autoinflammatory disease, but they are usually insufficient to
control symptoms and do not influence the underlying cause
of the disease in any of them.
• Glucocorticoids, generally used at medium or high doses,
may be effective when administered on demand (in short
courses) inmost of themonogenic conditions. In some TRAPS
patients, continuous administration of glucocorticoids may
be also useful. Anyway, because most patients will require a
biologic agent to control the disease activity, glucocorticoids
may be reserved as initial treatment to prove response or
may be also administered in a continuous or on-demand
modality for mild/non-severe cases. Glucocorticoids have
demonstrated special utility in FMF patients experiencing
protracted febrile myalgia and severe serositis (in a short
course at high doses) and in PFAPA patients (in a single high-
dose administration), representing the treatment of choice in
PFAPA syndrome.
• Among biologic agents, IL-1 blockers are the most
relevant and useful drugs in the treatment of the main
monogenic autoinflammatory diseases, especially in those
considered inflammasomopathies.
• Anakinra and canakinumab have FDA and EMA approval
as first-line treatment for CAPS patients, whereas rilonacept
has been approved only by the FDA. Both anakinra and
canakinumab are of clear utility in crFMF, TRAPS, and
HIDS/MKD patients, and canakinumab has been recently
approved by the FDA and EMA for these three conditions.
Anakinra has been used with success on demand in patients
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with all monogenic diseases and PFAPA syndrome and
therefore may be reserved for selected patients, mainly
for those presenting with prominent manifestations or
recognizable triggers preceding the attacks.
• Information regarding other alternative biologic agents is
scarce and extracted from small case series and case reports
including patients who did not respond to other biologics.
• Anti-TNF agents, and in particular, etanercept, seem to
exert some benefit in FMF patients with prominent articular
manifestations and also in TRAPS and HIDS/MKD patients.
• Tocilizumab (anti–IL-6 agent) has been successful in
controlling disease activity and improving proteinuria in
patients with FMF-associated amyloidosis and also in few
TRAPS and HIDS/MKD patients resistant to anti-TNF and/or
anti–IL-1 agents.
• The use of JAK inhibitors inmonogenic inflammasomopathies
is limited to the use of tofacitinib with good response in
few crFMF patients previously failing to IL-1, TNF, and IL-
6 blockers.
• The knowledge of genetic and pathogenesis of these
autoinflammatory diseases has to be encouraged in order
to discover new potential molecular targets leading to new
specific drugs.
• Further randomized clinical trials proving the efficacy
and safety of the currently promising biologic drugs
and the new potential agents and small molecules are
still needed.
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